Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T20:33:04.189Z.
Calculation as of: 2026-10-06T20:33:04.189Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2a19952d2edecd783a1a7aa32ab0a3489a492a6ad3733958836c0f0d47bc8061
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-03-09.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
EV/SALES RATIO AVG TTM
51.88x
EV/SALES RATIO AVG 3Y
28.39x
EV/SALES RATIO AVG 5Y
N/A
EV/SALES RATIO AVG 10Y
N/A
EV/SALES RATIO AVG 15Y
N/A
EV/SALES RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Spruce Biosciences, Inc.
Market Cap
$117.76M
EV/Sales Ratio
N/A
TTM Avg
51.88x
3Y Avg
28.39x
5Y Avg
N/A
Market Cap
$118.59M
EV/Sales Ratio
33.30x
TTM Avg
290.93x
3Y Avg
290.93x
5Y Avg
290.93x
Market Cap
$118.83M
EV/Sales Ratio
4.41x
TTM Avg
33.01x
3Y Avg
61.00x
5Y Avg
61.00x
Market Cap
$115.67M
EV/Sales Ratio
2.47x
TTM Avg
9.70x
3Y Avg
9.36x
5Y Avg
78.10x
Market Cap
$114.46M
EV/Sales Ratio
19.46x
TTM Avg
23.83x
3Y Avg
20.50x
5Y Avg
102.56x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Spruce Biosciences, Inc. (SPRB) | $117.76M | N/A | 51.88x | 28.39x | N/A |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $118.59M | 33.30x | 290.93x | 290.93x | 290.93x |
| MaxCyte, Inc. (MXCT)vs › | $116.76M | 3.83x | 3.87x | 7.07x | 9.90x |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.83M | 4.41x | 33.01x | 61.00x | 61.00x |
| Cibus, Inc. (CBUS)vs › | $119.84M | 30.40x | 52.83x | 97.39x | 88.07x |
| Foghorn Therapeutics Inc. (FHTX)vs › | $115.67M | 2.47x | 9.70x | 9.36x | 78.10x |
| Seer, Inc. (SEER)vs › | $120.41M | 8.43x | 5.92x | 6.73x | 48.81x |
| enGene Holdings Inc. (ENGN)vs › | $120.58M | N/A | N/A | N/A | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.46M | 19.46x | 23.83x | 20.50x | 102.56x |
| Genelux Corporation (GNLX)vs › | $113.89M | 13391.33x | 11863.26x | 8138.14x | 6150.74x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/SALES RATIO |
|---|---|
| 2026-03-09 | 36.80x |
| 2026-03-06 | 31.76x |
| 2026-03-05 | 30.07x |
| 2026-03-04 | 33.11x |
| 2026-03-03 | 31.73x |
| 2026-03-02 | 30.42x |
| 2026-02-27 | 31.01x |
| 2026-02-26 | 33.93x |
| 2026-02-25 | 34.07x |
| 2026-02-24 | 33.66x |
| 2026-02-23 | 29.91x |
| 2026-02-20 | 26.79x |
| 2026-02-19 | 29.14x |
| 2026-02-18 | 29.83x |
| 2026-02-17 | 33.68x |
| 2026-02-13 | 40.18x |
| 2026-02-12 | 53.65x |
| 2026-02-11 | 53.43x |
| 2026-02-10 | 54.19x |
| 2026-02-09 | 50.50x |
| 2026-02-06 | 45.11x |
| 2026-02-05 | 43.86x |
| 2026-02-04 | 50.63x |
| 2026-02-03 | 54.07x |
| 2026-02-02 | 49.63x |
| 2026-01-30 | 49.28x |
| 2026-01-29 | 51.14x |
| 2026-01-28 | 52.79x |
| 2026-01-27 | 54.68x |
| 2026-01-26 | 53.43x |
| 2026-01-23 | 52.48x |
| 2026-01-22 | 55.49x |
| 2026-01-21 | 50.38x |
| 2026-01-20 | 44.36x |
| 2026-01-16 | 46.03x |
| 2026-01-15 | 47.13x |
| 2026-01-14 | 49.94x |
| 2026-01-13 | 52.47x |
| 2026-01-12 | 49.48x |
| 2026-01-09 | 51.25x |
| 2026-01-08 | 46.16x |
| 2026-01-07 | 49.71x |
| 2026-01-06 | 51.71x |
| 2026-01-05 | 52.97x |
| 2026-01-02 | 59.90x |
| 2025-12-31 | 57.00x |
| 2025-12-30 | 53.41x |
| 2025-12-29 | 53.11x |
| 2025-12-26 | 55.89x |
| 2025-12-24 | 54.49x |
| 2025-12-23 | 54.28x |
| 2025-12-22 | 53.53x |
| 2025-12-19 | 50.24x |
| 2025-12-18 | 48.65x |
| 2025-12-17 | 47.89x |
| 2025-12-16 | 49.64x |
| 2025-12-15 | 51.80x |
| 2025-12-12 | 54.00x |
| 2025-12-11 | 58.05x |
| 2025-12-10 | 55.83x |
| 2025-12-09 | 63.49x |
| 2025-12-08 | 52.61x |
| 2025-12-05 | 51.25x |
| 2025-12-04 | 59.69x |
| 2025-12-03 | 59.46x |
| 2025-12-02 | 58.69x |
| 2025-12-01 | 53.77x |
| 2025-11-28 | 67.41x |
| 2025-11-26 | 75.49x |
| 2025-11-25 | 71.10x |
| 2025-11-24 | 73.07x |
| 2025-11-21 | 71.45x |
| 2025-11-20 | 69.52x |
| 2025-11-19 | 76.30x |
| 2025-11-18 | 79.53x |
| 2025-11-17 | 74.55x |
| 2025-11-14 | 72.54x |
| 2025-11-13 | 77.57x |
| 2025-11-12 | 69.19x |
| 2025-11-11 | 77.64x |
| 2025-11-10 | 42.75x |
| 2025-11-07 | 48.06x |
| 2025-11-06 | 44.47x |
| 2025-11-05 | 44.80x |
| 2025-11-04 | 37.77x |
| 2025-11-03 | 37.68x |
| 2025-10-31 | 40.18x |
| 2025-10-30 | 38.85x |
| 2025-10-29 | 43.86x |
| 2025-10-28 | 46.90x |
| 2025-10-27 | 46.21x |
| 2025-10-24 | 50.98x |
| 2025-10-23 | 49.43x |
| 2025-10-22 | 54.38x |
| 2025-10-21 | 49.25x |
| 2025-10-20 | 57.94x |
| 2025-10-17 | 62.45x |
| 2025-10-16 | 61.88x |
| 2025-10-15 | 63.03x |
| 2025-10-14 | 71.36x |
| 2025-10-13 | 63.00x |
| 2025-10-10 | 69.81x |
| 2025-10-09 | 70.61x |
| 2025-10-08 | 63.50x |
| 2025-10-07 | 74.01x |
| 2025-10-06 | 49.65x |
| 2024-03-13 | 15.59x |
| 2024-03-12 | 14.32x |
| 2024-03-11 | 15.20x |
| 2024-03-08 | 15.15x |
| 2024-03-07 | 16.69x |
| 2024-03-06 | 15.59x |
| 2024-03-05 | 13.88x |
| 2024-03-04 | 16.58x |
| 2024-03-01 | 16.03x |
| 2024-02-29 | 14.54x |
| 2024-02-28 | 16.58x |
| 2024-02-27 | 15.37x |
| 2024-02-26 | 16.69x |
| 2024-02-23 | 17.24x |
| 2024-02-22 | 16.53x |
| 2024-02-21 | 15.42x |
| 2024-02-20 | 15.86x |
| 2024-02-16 | 14.65x |
| 2024-02-15 | 14.87x |
| 2024-02-14 | 13.99x |
| 2024-02-13 | 11.90x |
| 2024-02-12 | 11.29x |
| 2024-02-09 | 10.85x |
| 2024-02-08 | 8.92x |
| 2024-02-07 | 9.53x |
| 2024-02-06 | 7.54x |
| 2024-02-05 | 6.66x |
| 2024-02-02 | 6.38x |
| 2024-02-01 | 5.94x |
| 2024-01-31 | 7.16x |
| 2024-01-30 | 5.89x |
| 2024-01-29 | 6.55x |
| 2024-01-26 | 5.72x |
| 2024-01-25 | 3.79x |
| 2024-01-24 | 1.15x |
| 2024-01-23 | 0.87x |
| 2024-01-22 | 0.43x |
| 2024-01-19 | 0.16x |
| 2024-01-18 | 0.21x |
| 2024-01-17 | 0.32x |
| 2024-01-16 | 1.09x |
| 2024-01-12 | 0.65x |
| 2024-01-11 | 1.64x |
| 2024-01-10 | 2.31x |
| 2024-01-09 | 1.81x |
| 2024-01-08 | 2.42x |
| 2024-01-05 | 3.19x |
| 2024-01-04 | 2.86x |
| 2024-01-03 | 2.03x |
| 2024-01-02 | 3.30x |
| 2023-12-29 | 3.13x |
| 2023-12-28 | 2.69x |
| 2023-12-27 | 1.92x |
| 2023-12-26 | 0.65x |
| 2023-09-22 | 0.51x |
| 2023-09-21 | 1.09x |
| 2023-09-20 | 1.18x |
| 2023-09-19 | 0.99x |
| 2023-09-18 | 0.90x |
| 2023-09-15 | 1.28x |
| 2023-09-14 | 1.18x |
| 2023-09-13 | 1.57x |
| 2023-09-12 | 2.05x |
| 2023-08-18 | 0.23x |
| 2023-08-17 | 0.04x |
| 2023-08-14 | 0.08x |
| 2023-08-11 | 0.63x |
| 2023-08-10 | 1.34x |
| 2023-08-09 | 1.03x |
| 2023-08-08 | 0.39x |
| 2023-08-04 | 1.82x |
| 2023-08-03 | 2.77x |
| 2023-08-02 | 1.66x |
| 2023-08-01 | 1.82x |
| 2023-07-31 | 1.03x |
| 2023-07-28 | 1.03x |
| 2023-07-27 | 0.23x |
| 2023-07-26 | 1.98x |
| 2023-07-21 | 0.55x |
| 2023-07-20 | 0.55x |
| 2023-06-26 | 0.55x |
| 2023-06-23 | 2.14x |
| 2023-06-22 | 0.23x |
| 2023-06-21 | 1.34x |
| 2023-06-20 | 1.66x |
| 2023-06-16 | 3.09x |
| 2023-06-15 | 2.77x |
| 2023-06-14 | 2.93x |
| 2023-06-13 | 3.40x |
| 2023-06-12 | 1.82x |
| 2023-06-09 | 1.98x |
| 2023-06-08 | 2.29x |
| 2023-06-07 | 2.77x |
| 2023-06-06 | 2.45x |
| 2023-06-05 | 2.45x |
| 2023-06-02 | 2.37x |
| 2023-06-01 | 2.14x |
| 2023-05-31 | 3.88x |
| 2023-05-30 | 3.40x |
| 2023-05-26 | 3.88x |
| 2023-05-25 | 1.18x |
| 2023-05-24 | 6.57x |
| 2023-05-23 | 4.19x |
| 2023-05-22 | 4.35x |
| 2023-05-19 | 2.29x |
| 2023-05-18 | 1.18x |
| 2023-05-17 | 1.82x |
| 2023-05-16 | 0.23x |
